Source: European Medicines Agency (EU) Revision Year: 2019 Publisher: UCB Pharma S.A., Allée de la Recherche 60, B-1070, Bruxelles, Belgium
Neupro 4 mg/24 h transdermal patch.
Neupro 6 mg/24 h transdermal patch.
Neupro 8 mg/24 h transdermal patch.
| Pharmaceutical Form |
|---|
|
Transdermal patch. Thin, matrix-type, square-shaped with rounded edges, consisting of three layers. Neupro 4 mg/24 h transdermal patch: The outside of the backing layer is tan-coloured and imprinted with ‘Neupro 4 mg/24 h’. Neupro 6 mg/24 h transdermal patch: The outside of the backing layer is tan-coloured and imprinted with ‘Neupro 6 mg/24 h’. Neupro 8 mg/24 h transdermal patch: The outside of the backing layer is tan-coloured and imprinted with ‘Neupro 8 mg/24 h’. |
Neupro 4 mg/24 h transdermal patch: Each patch releases 4 mg of rotigotine per 24 hours. Each patch of 20 cm² contains 9.0 mg of rotigotine.
Neupro 6 mg/24 h transdermal patch: Each patch releases 6 mg of rotigotine per 24 hours. Each patch of 30 cm² contains 13.5 mg of rotigotine.
Neupro 8 mg/24 h transdermal patch: Each patch releases 8 mg of rotigotine per 24 hours. Each patch of 40 cm² contains 18.0 mg of rotigotine.
For the full list of excipients, see section 6.1.
| Active Ingredient | Description | |
|---|---|---|
| Rotigotine |
Rotigotine is a non-ergolinic dopamine agonist for the treatment of signs and symptoms of Parkinson’s disease and Restless Legs Syndrome. |
| List of Excipients |
|---|
|
Backing layer: Polyester film, siliconized, aluminized, colour coated with a pigment (titanium dioxide (E171), pigment yellow 95, pigment red 166) layer and imprinted (pigment red 144, pigment yellow 95, pigment black 7) Self adhesive matrix layer: Poly(dimethylsiloxane, trimethylsilyl silicate)-copolymerisate Release liner: Transparent fluoropolymer coated polyester film |
Peel off sachet in a plastic box: One side is composed of an ethylene copolymer (innermost layer), an aluminium foil, low density polyethylene film and paper; the other side is composed of polyethylene (innermost layer), aluminium, ethylene copolymer and paper.
The box contains 7, 14, 28, 30 or 84 (multipack containing 3 packs of 28) transdermal patches, individually sealed in sachets.
Not all pack sizes may be marketed.
UCB Pharma S.A., Allée de la Recherche 60, B-1070, Bruxelles, Belgium
Neupro 4 mg/24 h transdermal patch:
EU/1/05/331/004
EU/1/05/331/005
EU/1/05/331/021
EU/1/05/331/024
EU/1/05/331/059
Neupro 6 mg/24 h transdermal patch:
EU/1/05/331/007
EU/1/05/331/008
EU/1/05/331/027
EU/1/05/331/030
EU/1/05/331/060
Neupro 8 mg/24 h transdermal patch:
EU/1/05/331/010
EU/1/05/331/011
EU/1/05/331/033
EU/1/05/331/036
EU/1/05/331/061
Date of first authorisation: 15 February 2006
Date of latest renewal: 22 January 2016
| Drug | Countries | |
|---|---|---|
| NEUPRO | Austria, Australia, Brazil, Canada, Cyprus, Estonia, Spain, Finland, France, Hong Kong, Croatia, Ireland, Italy, Japan, Lithuania, Netherlands, Poland, Romania, Singapore, United Kingdom, United States |
© All content on this website, including data entry, data processing, decision support tools, "RxReasoner" logo and graphics, is the intellectual property of RxReasoner and is protected by copyright laws. Unauthorized reproduction or distribution of any part of this content without explicit written permission from RxReasoner is strictly prohibited. Any third-party content used on this site is acknowledged and utilized under fair use principles.
